Luis
Supply Chain at Apellis
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSWe challenge conventional thinking and always question if there's a better way.
Join UsPatricia
Quality Assurance at Apellis